Fujirebio产品代理
Fujirebio产品代理
Fujirebio 是一家以研发为导向的公司，不断为全球体外诊断行业开发具有高临床价值的新技术和独特的标志物。我们的集团使命是在医疗保健领域创造新价值，从而为人类健康和医疗保健的未来做出贡献。
首页 关于富士瑞生物
我们位于日本、亚洲、欧洲和美国的全球团队专注于为我们的客户和合作伙伴提供最高质量标准的产品。我们重视与业内其他领先公司的合作伙伴关系，共享知识、能力和关键材料，以便在各种平台上提供、开发或制造诊断解决方案。
通过这种商业模式，我们确保世界需要的可能改变生活的诊断标志物在尽可能短的时间内到达最广泛的全球受众。
创新的传承
Fujirebio 于 1950 年在日本成立。它于 1966 年开发了第一个 TPHA 诊断试剂盒，这是梅毒检测的黄金标准。从那时起，我们建立了创新、开发、制造和营销高质量体外诊断检测解决方案的悠久传统全世界。多年来，收购 Centocor Diagnostics、CanAg Diagnostics 和 Innogenetics 进一步增强了我们在各个临床领域的能力和专业知识。今天，与世界顶级商业实验室之一 (SRL, Inc.) 密切合作，该实验室是 H.U. 的另一个实体。 Fujrebio 集团在比以往任何时候都更强大的诊断市场上拥有专业知识和经验的结合。
开创性体外诊断解决方案的先驱
我们旅程中的重要里程碑包括开发出世界上第一台全自动化学发光酶免疫分析 (CLEIA) 仪器 - 更为人所知的是 Lumipulse® - 今天在世界各地使用。我们的产品线涵盖从专业手动和自动测试到全自动常规测试解决方案的范围。此外，我们提供神经退行性疾病、传染病和肿瘤学检测领域的金标准检测，并继续提供涵盖多种其他疾病状态的新型和常规生物标志物，包括 SARS-COV-2 感染。
灵活可靠的业务合作伙伴
我们位于日本、瑞典、比利时和美国的研发团队和生产团队致力于开发和制造最高质量的产品。这为我们赢得了直接客户和领先诊断公司全球合作伙伴的良好声誉。 Fujirebio 集团公司通过了 ISO 13485、ISO 9001、EN46001 和 ISO 14001* 认证。最重要的是，我们的全球团队为新生物标志物或系统开发的每个阶段带来的洞察力和专业知识使我们的客户和合作伙伴处于早期诊断和最先进的医疗保健解决方案的最前沿。
A proven pioneer and partner in the diagnostic industry
Fujirebio is an R&D-driven company constantly developing new technology and unique markers with high clinical value to the global in vitro diagnostics industry. Our group mission is to create new value in healthcare and thereby contribute to human health and the future of medical care.
Home About Fujirebio
Our global teams located in Japan, Asia, Europe and US focus on delivering products with the highest quality standards to our customers and partners. We value partnerships with other leading companies in the industry, sharing knowledge, capabilities, and key materials in order to supply, develop or manufacture diagnostic solutions on a wide variety of platforms.
Through this business model, we ensure that the potentially life-changing diagnostic markers that the world needs reach the widest global audience in the shortest possible time.
A heritage of innovation
Fujirebio started in Japan in 1950. It developed its first TPHA diagnostics kit, the gold standard for syphilis testing, in 1966. Since then, we have built a strong tradition for innovating, developing, manufacturing and marketing high-quality in vitro diagnostics testing solutions worldwide. Over the years, the acquisition of Centocor Diagnostics, CanAg Diagnostics and Innogenetics have even further bolstered our capabilities and expertise in various clinical areas. Today, working closely with one of the world’s top commercial laboratories (SRL, Inc.), which is another entity within the H.U. Group, Fujrebio enjoys a combination of expertise and experience in the diagnostics market that is more potent than ever.
Pioneers of ground-breaking IVD solutions
Key milestones in our journey include developing the world’s first fully automated chemiluminescent enzyme immunoassay (CLEIA) instruments – better known as Lumipulse® – which are used all around the world today. Our product lines span the range from specialized manual and automated testing to fully automated routine testing solutions. In addition, we provide gold standard assays in the fields of
neurodegeneration, infectious disease, and oncology testing, and we continue to offer both novel and routine biomarkers that cover a wide variety of other disease states including infection with SARS-COV-2.
Flexible and reliable business partner
Our R&D teams and production teams located in Japan, Sweden, Belgium and US are committed to developing and manufacturing products with the highest quality. This has earned us a strong reputation with our direct customers and global partners at leading diagnostic companies. The Fujirebio group of companies are certified as compliant with ISO 13485, ISO 9001, EN46001 and ISO 14001*. Above all, the insights and know-how that our global team bring to each stage in the development of a new biomarker or system keep our customers and partners at the forefront of early diagnostics and state-of-the-art healthcare solutions.
